Detection of metallo-β-lactamase producing Pseudomonas aeruginosa is crucial for the optimal treatment of patients; however there are limited studies on metallo-β-lactamase producing P. aeruginosa isolates from West Azarbayejan, Iran. This study was designed to detect the metallo-β-lactamase in P. aeruginosa isolates. One hundred isolates were collected from clinical specimens submitted to hospital diagnostic laboratories in Urmia/Iran from July to September 2010. The susceptibilities of the isolates to different classes of antibiotics were tested using Müller-Hinton agar disk diffusion method. All isolates of P. aeruginosa were subjected to determination of minimum inhibitory concentrations )MICs) against Imipenem. Imipenem non-susceptible isolates were investigated for metallo-β-lactamase production by the combined disk method. The rates of resistances to antibiotics, as were determined, is as follows: kanamycin (91%), Tobramycin (34%), Ciprofloxacin (16%), Colistin (68%), Ticarcillin (46%), Amikacin (16%), Norfloxacin (23%), gentamicin (33%), Ceftazidime (62%), Ceftizoxime (69%), and Cefepime (39%). Seventy nine isolates (79%) were sensitive (MIC ≤ 4 mg/L) and 21 isolate (21%) were resistant to Imipenem (MIC ≥ 8 mg/L). The rates of resistance to different antibiotics were much higher in Imipenem resistant isolates. Detection of metallo-β-lactamase producing isolates among Imipenem non-susceptible isolates of P. aeruginosa revealed that seven isolates (33.3%) were metallo-β-lactamase positive. Metallo-β-lactamase positive isolates showed high resistances to all tested antibiotics. This result suggests that metallo-β-lactamase producing isolates in hospitals may cause serious infections which can lead to failure in patient's antibiotic therapy.
INTRODUCTION
Pseudomonas aeruginosa is a major bacterium causing nosocomial infections, and the development of multidrug resistance of this bacterium to different classes of antibacterial agents has become a main problem (Thuong et al., 2003; Lockhart et al., 2007; Algun et al., *Corresponding author. E-mail: n_jazani@umsu.ac.ir, n_jazani@yahoo.com. Tel: +98-441 -3449548, +98-914 -3464234. Fax: +98-441-2780800. 2004 ).
This opportunistic bacterium can quickly colonize in immunocompromised host and infect the burn and wound sites, disseminate to the bloodstream and induce endotoxic shock, the clinical outcome in these patients can lead to sepsis which is often fatal. As mentioned previously, antibiotics such as β-lactams are generally ineffective against most serious infections caused by P. aeruginosa (Dale et al., 2004) , Also resistance to extended spectrum β-lactams has been frequently observed in P. aeruoginosa (Kahan et al., 1983; Saderi et al., 2008) . Several mechanisms for resistance to extended spectrum β-lactams have been reported before, but the common form of resistance is mediated by hydrolyzing β-lactamases. Based on molecular studies, carbapenem hydrolyzing enzymes are classified into four groups A, B, C and D (Ambler, 1980) . The metallo-β-lactamases (MBLs) belong to group B and requiring divalent cations as cofactors for their enzyme activity. The MBLs efficiently hydrolyze all β-lactams, except aztreonam in vitro (Bush et al., 1995) . P. aeruoginosa producing MBLs was first reported from Japan in 1991 (Watanabe et al., 1991) and within a short time period has been reported from various parts of the world (Lee et al., 2004a; Yan et al., 2001; Lagatolla et al., 2004; Toleman et al., 2004) .
Several phenotypic methods are available for the detection of MBL producing bacteria. All the methods are based on the ability of metal chelators such as ethylenediaminetetraacetic acid (EDTA) to inhibit the activity of MBLs. For example the double disk synergy tests using EDTA with Imipenem (Lee et al., 2004a; Yan et al., 2004) . Since MBL producing P. aeruginosa is often resistant not only to all β lactams, but also aminoglycosides, and fluoroquinolones, there are often no drugs to treat infection with these bacteria. On the other hand detection of MBL produced P. aeruginosa is crucial for the optimal treatment of patients particularly in the cases of critically ill and to control the spread of resistance (Oie et al., 2009) . There are limited studies available on MBL producing P. aeruginosa isolates from West Azerbaijan, Iran. Therefore, this study was designed to detect the MBL in P. aeruginosa isolates obtained from hospitalized patients in Urmia, Iran.
MATERIALS AND METHODS

Bacterial isolates
A total of 100 isolates were collected from clinical specimens (wound, urine, sputum, blood and pleural fluid) submitted to hospital diagnostic laboratories in Urmia/Iran from July to September 2010. Fifty one isolates were obtained from male patients and 49 isolate from female patients, 36 isolates recovered from outpatients and 64 isolates were obtained from in-patients. The isolates were further processed by the following standard methods to identify as P. aeruginosa: Gram stain, colony morphology, pigment production, triple suger iron agar reaction (Himedia laboratories, Mumbai), oxidase test, IMViC tests (Himedia laboratories, Mumbai), ability of growth in 42°C, O/F reaction and growth on cetrimide agar (Himedia laboratories, Mumbai). Isolated bacteria were maintained for long storage on skimmed milk medium, biological laboratories (BBL) by adding 10% glycerol(Merck) in -60°C, cultures were maintained for daily use on nutrient agar (BBL) slants on 4°C. P. aeruoginosa ATCC 27853 was used as control.
Antimicrobial susceptibility testing
The susceptibilities of isolates to different antibiotics were tested using agar disk diffusion method (Bauer et al., 1966) in accordance with national committee for clinical laboratory standards (NCCLS) incorporating standard strain of P. aeruginosa (ATCC 27853). To represents the different classes of antimicrobial agents commonly used for the treatment of P. aeruginosa infections, we used Kanamycin (30 mcg), Tobramycin (10 mcg), Ciprofloxacin (5 mcg), Colistin (10 mcg), Ticarcillin (75 mcg), Amikacin (30 mcg), Norfloxacin (10 mcg), Gentamicin (10 mcg), Ceftazidime (30 mcg), Ceftizoxime (30 mcg), and Cefepime (30 mcg) (Hi-media, Mombay, India). The definition of multi drug resistant P. aeruginosa was established as isolates resistant to at least three drugs in four different classes including: β-lactams, carbapenems, aminoglycosides, and fluoroquinolones (Obritsch et al., 2005) .
Determination of MIC of Imipenem for isolates
All isolates of P. aeruginosa were subjected to determine minimum inhibitory concentrations )MICs) against Imipenem. The E-test method has been used for MIC determination according to the manufactures instructions. In brief, bacterial suspensions was prepared from fresh colonies and the concentration has been adjusted to 0.5 McFarland turbidity. Each isolate was inoculated by streaking the bacteria all over a mueller hinton agar (MHA) plate. An Etest strip of Imipenem (AB Biodisk Sweden) (from 0.002 to 32 µg/mL) was placed on the surface of cultured media, after overnight incubation at 36 ± 0.5°C, MIC has been determined and the sensitive, intermediate and resistant phenotypes were determined according to the European committee on antimicrobial susceptibility testing (EUCAST) guideline (http://www.eucast.org/clinical_breakpoints/).
Detection of MBL producing isolates by Imipenem-EDTA combined disk method
Imipenem non-susceptible isolates were investigated for MBL production by this method. The bacterial suspension with turbidity equivalent to 0.5 McFarland was prepared and cultured on MHA by streaking method. Two Imipenem disks (10 µg) have been placed on the agar surface and 5 µl of 0.5 M EDTA solution was added only to one of the disks. After overnight incubation at 36 ± 0.5°C, the inhibition zones of Imipenem disks with or without EDTA were measured and compared. An increase of seven mm or more in the zone diameter for Imipenem + EDTA disk in compare with Imipenem disk was considered as a MBL producing isolate (Lee et al., 2001) .
RESULTS
Bacterial isolates
A total of 100 clinical isolates of P. aeruginosa were collected from three University Hospitals in Urmia, northwest of Iran. The frequency of specimen's sources of P. aeruginosa isolates is shown in Figure 1 .
Antibiotic susceptibility testing based on disk diffusion method
Antibiotic susceptibility testing results against 11 antibiotics are presented in Figure 2 . P. aeruginosa isolates showed high resistances to Kanamycin, Ceftizoxime and Colistin respectively, on the other hand the most effective antibiotics were Amikacin and Ciprofloxacin. 
Determination of MIC of Imipenem for isolates
Determination of MICs for Imipenem by Etest method revealed that 16 isolates were resistant to all tested concentrations of Imipenem, the mean MIC ± SD value for the remind 84 isolates was 1.17 ± 1.51 µg/mL. According to the EUCAST breakpoint for Imipenem, 79 isolates (79%) were sensitive (MIC ≤ 4 mg/L) and 21 isolate (21%) were resistant to Imipenem (MIC ≥ 8 mg/L).
Prevalence of antibiotic resistance among susceptible and resistant isolates to Imipenem
The rate of resistance to different antibiotics was much higher in 21 Imipenem resistant isolates in comparison with79 Imipenem non resistant isolates (Figure 3) .
Detection of MBL producing isolates by Imipenem-EDTA combined disk method
Detection of MBL producing isolates among Imipenem non-susceptible isolates of P. aeruginosa by this phenotypic method revealed that seven isolates (33.3%) were MBL positive (cut off value ≥ 7 mm).
Comparison of the rate of antibiotic resistance in MBL positive versus MBL negative isolates
MBL positive isolates showed very high resistances to all tested antibiotics. Five isolates (71.4%) were resistant to all antibiotics; only two isolates (28.5%) were sensitive to Amikacin and one isolate revealed intermediate resistance to Norfloxacin (Table 1) .
DISCUSSION
P. aeruginosa is one of the most important hospital acquired pathogens. Recently obtained hospital isolates of P. aeruginosa are often multi drug resistant to many classes of antimicrobial agents, including fluoroquinolones, β-lactams and even aminoglycosides. Carbapenems are the most potent β-lactam antibiotics, which are active even against extended spectrum β-lactamase producing gram-negative bacteria. However, due to acquired MBL production, carbapenem resistance in P. aeruginosa and some of the other gram negative bacilli has been reported in many countries (Walsh et al., 2005) .
The data obtained in this research indicate that the prevalence of resistance of P. aeruginosa isolates to tested antibiotics was relatively high. To our findings the best antibiotics for treatment of P. aeruoginosa infections were Amikacin and Ciprofloxacin followed by Norfloxacin and Gentamicin (Figure 2 ). The rate of resistance to Ceftazidime increased in comparison with the previous studies has been done before in the same hospitals (Yousefi et al., 2010) . On the other hand the resistance rate to some of antibiotics such as Amikacin, Ciprofloxacin and Gentamicin showed decreases in comparison with the previous studies in the same hospitals. This findings in part may be due to wards where the samples has been taken from them; as in the present study, most of the samples has been obtained from pediatrics ward, but in the previous study has been done by Yousefi et al. (August 2007 to October 2008 many of the isolates has been collected from patients in intensive care unit (ICU), internal or burn wards, also the optimal useage of existing antimicrobial agents in treatment of P. aeruginosa infections or the use of alternative treatment options, in the studied hospitals in the recent years may play a role in decrease of antimicrobial resistance in the study area (Yousefi et al., 2010) . Increasing resistance to the various antipseudomonas agents has been reported worldwide and this poses a serious problem in therapeutic management of P. aeuroginosa infections (Carmeli et al., 1999 , Obritsch et al., 2004 . Approximately 58% of P. aeruginosa isolates in our study were multi-drug resistant strains, however the prevalence of multi-drug resistance isolates of P. aeruroginosa in the other studies are much lower than our study (Ohara et al., 2007) .
In our study 21% of isolates were resistant to Imipenem, this finding is relatively in agreement with previous studies has been done by others which reported the prevalence of Imipenem resistant isolates of P. aeruoginosa 38.28% (Saderi et al., 2008) and 27.47% (Yousefi et al., 2010) , the defferences in the reported values between present study and the previous studies may be due to the fewer sample size in the present study. Analysis of the data generated by the participating hospitals in Korea during 1998 till 2004 showed an alarming rise in the imipenem resistance rates of P. aeruginosa; from 19 to 24% (Lee et al., 2004b; 2006) . The results of the present study showed that 33% of Imipenem non-susceptible isolates were MBL positive, the previous studies from Korea in 2009 showed that 10.8% of Imipenem non-susceptible isolates were MBL positive (Oie et al., 2009 ), on the other hand, previous studies from Azarbayejan, Iran showed that 56.73% of Imipenem non-susceptible isolates were MBL positive by Imipenem-EDTA combined disk method (Yousefi et al., 2011) . In the present study 95.2 and 100% of Imipenem non-susceptible isolates and MBL producing isolates were multi drug resistant isolates, these findings are in accordance with results obtained by Magalhes et al. (2005) which reported that MBL positive isolates were resistant to main anti-pseudomonas drugs. In conclusion, the clinical significance of P. aeruginosa isolates possessing Metallo-β-lactamase enzymes are ultimately judged by their ability to confer in vivo resistance to betalactams and even other classes of antipseudomonas antibiotics, ultimately lead to the patient fails antibiotic therapy. As shown in the present study, Metallo-β-lactamase producing P. aeruginosa isolates is prevalent in Urmia, West Azerbaijan in Iran may cause serious problems in treatment of infections caused by theses strains of P. aeruginosa.
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